本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
JEDDAH, Saudi Arabia, May 15, 2023 /PRNewswire/ -- Under the patronage of The Custodian of The Two Holy Mosques, King Abdullah bin Abdulaziz Al Saud, the Islamic Development Bank (IsDB) Group's Annual Meetings successfully concluded, today, in Jeddah, Kingdom of Saudi Arabia. Chairman of IsDB Group and Benin’s Minister of Economy and Finance concluding the 2023 IsDB Group Annual Meetings The four-day event attracted 4,452 participants from 90 countries around the world as well as 89 leading regional and international organizations working toward sustainable development. During the event, held under the theme, "Partnerships to Fend off Crises," IsDB Group announced several projects and signed financing agreements with 24 member countries (MCs) worth US$ 5.4 billion to address pressing challenges that hinder growth in the Global South, with a focus on health, agriculture, food security, SMEs, education and humanitarian assistance, amongst others. IsDB President and Group Chairman, H.E. Dr. Muhammad Al Jasser, stated, "Over the past four days, we have reviewed development-related issues with our partners and member countries. We discussed the current situation and the future of the IsDB Group, reaching a number of important decisions in the process. The results of these annual meetings are certain to pave the way for further success to come." During the event, the IsDB Group announced several key projects and signed agreements reinforcing its commitment to financing sustainable development projects in its MCs. The IsDB Group Board of Executive Directors approved financing valued at more than US$ 558 million for six projects focusing on supporting inclusive growth and infrastructure development in MCs. The IsDB Group also launched its revamped Member Country Partnership Strategy documents for Uzbekistan, Pakistan and Niger which will activate the IsDB Group Country Engagement Framework within the respective countries to support multilateral development and growth. In another development, IsDB, as the Trustee of the Afghanistan Humanitarian Trust Fund, signed seven agreements for inclusive sustainable development projects in Afghanistan, with a total consideration of US$ 8,098,180, which includes grants from the King Salman Humanitarian Aid and Relief Center. IsDB and its international development partners also launched the second phase of its Lives and Livelihoods Fund (LLF 2.0) which aims to mobilize resources that support economic development across 32 of the less privileged MCs of the Bank. IsDB has committed a contribution of US$ 325 million in highly concessional loans to LLF 2.0, bringing the total grant contributions to the fund to US$ 200 million. The four-day event also included high-level plenary sessions, technical symposiums, and side events focusing on a wide range of topics, such as poverty alleviation, infrastructure development, women and youth empowerment, and climate action. CONTACT Walid El Majzoub TRACCS Tel: 00971-4-3672530 Email: Walid.majzoub@traccs.net His Excellency Dr. Muhammad Al Jasser, Chairman of the Islamic Development Bank (IsDB) Group, and Romuald Wadagni, minister of economy and finance of Benin at the closing press conference of the 2023 IsDB Group Annual Meetings
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly"). ABL Bio and Lilly are currently conducting joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various modalities. In parallel with strengthening its collaboration with Lilly, ABL Bio plans to accelerate R&D on its core technologies—including the bispecific antibody platform 'Grabody', bispecific ADCs, and dual-payload ADCs—using the newly secured funding. Sang Hoon Lee, CEO of ABL Bio said, "With the completion of the relevant administrative procedures, including the HSR Act, ABL Bio will receive the upfront payment and equity investment from Lilly. The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas such as obesity and muscle disorders. ABL Bio also intends to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and focus on advancing next-generation ADC programs." Meanwhile, on November 12 and 14, ABL Bio signed a license, research and collaboration agreement for Grabody platform with Lilly valued at USD 2.602 billion (including a USD 40 million upfront payment), as well as a USD 15 million equity investment agreement. Based on these agreements, ABL Bio explores a broad range of collaborative opportunities with Lilly to develop therapies from a long-term perspective. About ABL Bio ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform 'Grabody'. Clinical projects for 8 pipelines, including ABL301 (SAR446159), ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105 (YH32367), ABL104 (YH32364), ABL103, and ABL202 (CS5001/LCB71), are underway for different indications in various countries, including the United States, China, Australia, and Korea. Following the completion of the Phase 1 clinical trial of ABL301 (SAR446159), Sanofi will conduct the subsequent clinical studies. ABL001 (tovecimig) has received Fast Track designation by the U.S. Food and Drug Administration (FDA). In addition, ABL111 (givastomig), co-developed with NovaBridge, has presented encouraging data from the Phase 1b clinical trial evaluating the triple combination therapy with nivolumab and chemotherapy in ESMO GI 2025. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Ascentium has partnered with Standard Chartered to make cross-border expansion simpler and faster for businesses across Asia-Pacific (APAC). Formalised through a Memorandum of Understanding, the collaboration is designed to empower clients to seize opportunities in the region with practical, clear solutions. Launching in Hong Kong with a fast-track banking service for Ascentium clients, the partnership helps businesses open accounts quickly and begin operations without unnecessary delays. While Hong Kong is the starting point, both organisations plan to extend this model to other APAC markets in the near future. The partnership also creates a connected network across APAC, giving clients direct access to Standard Chartered's referral network in Singapore, Mainland China, Hong Kong, Malaysia, Vietnam, and India. By combining banking efficiency with Ascentium's corporate services expertise, the collaboration positions Ascentium as a one-stop growth platform for businesses looking to scale across borders with confidence. Beyond delivering a smarter way to bank, Ascentium and Standard Chartered are opening avenues for businesses to connect, grow, and thrive through joint marketing initiatives and co-hosted events in markets including Vietnam and Mainland China which are already underway. Ascentium will also join Standard Chartered's Global Chinese Services network, establishing a connection to Chinese corporates and reinforcing both organisations' commitment to supporting businesses with global ambitions. Wendy Wang, Founding Management and Group President of Ascentium, said: "This partnership reflects a shared mission to make expansion simpler, faster, and more human. By bringing together leaders in banking and corporate services, we've created a powerhouse that gives businesses clarity and confidence from day one. We're excited to embark on this journey with Standard Chartered, and to work together in delivering this model to more markets across Asia." Xie Wen, Global Head, SME Banking at Standard Chartered, added: "As a leading international wealth manager, our goal is to make banking simple and accessible for businesses with global ambitions. Our partnership with Ascentium allows us to offer our clients a smoother, end-to-end experience, from account opening to cross-border expansion, helping businesses scale with confidence." (From left to right) Tony So, Head, SME Banking, Hong Kong & Greater Bay Area, and Xie Wen, Global Head, SME Banking, both from Standard Chartered, Wendy Wang, Founding Management & Group President, and Gary Tok, Group Chief Commercial Officer, both from Ascentium. - END – About Ascentium Ascentium is a leading global business services platform dedicated to helping businesses and individuals scale greater heights. Headquartered in Singapore, we drive extraordinary growth through expert people, purpose-led technology, and an unwavering commitment to service excellence. With over 2,500 professionals across 45 cities in 23 markets globally, we deliver integrated solutions in corporate services, finance and accounting, fund administration, human resources, and fiduciary and trust services. Serving more than 60,000 client entities across diverse industries, Ascentium combines specialised expertise with innovative, technology-enabled solutions to help clients navigate complexity and unlock new opportunities for sustainable growth. For more information, visit: ascentium.com About Standard Chartered We are a leading international banking group, with a presence in 54 of the world's most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good. Standard Chartered PLC is listed on the London and Hong Kong stock exchanges. For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.
BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner. Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. ("Jacoray") for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment and an additional RMB 75 million as a second instalment milestone payment). Upon completion, Beijing Jacobio, Oceanpine Capital, and the industry partner will hold 10%, 80%, and 10% of Jacoray, respectively. Jacoray is the project company for Jacobio's early-stage cardiovascular research program. The transaction aligns with Jacobio's strategic focus on developing innovative oncology therapies—including KRAS and iADC —by optimizing capital allocation, enhancing operational efficiency, and adopting a risk-sharing model to retain long-term project value. Proceeds from the transaction will primarily support R&D, production, and commercialization of Jacobio's Pan-KRAS inhibitor and other oncology assets. Mr. Dave Chenn, Founder, CEO and Managing Partner of Oceanpine Capital, said: "Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalization of China's biotech innovation." Dr. Yinxiang Wang, Chairman of Jacobio, said, "This partnership with Oceanpine Capital strengthens our strategic focus on oncology innovation and reinforces our commitment to advancing next-generation cancer therapies." About Jacobio Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company's core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio's R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries. For more information, please visit: http://www.jacobiopharma.com About Oceanpine Capital Oceanpine Capital, founded in 2018, is a professional investment management firm dedicated to long-term value investing. With a mission to drive technological innovation, and focus on cutting-edge sectors such as advanced technology, green technology and life sciences, with assets under management exceeding RMB25 billion.
To strengthen ServiceNow capabilities and drive enterprise digital transformation SINGAPORE, Oct. 8, 2025 /PRNewswire/ -- Apar Technologies, a global consulting and technology services leader, today announced a strategic investment in Medeon, a Singapore-headquartered and fast-growing company specializing in ServiceNow AI consulting and solutions. This investment enhances Apar's enterprise workflow and digital transformation offerings for its clients and enables Medeon to expand its market reach — together, delivering greater value across global markets. Medeon brings together former ServiceNow and Google AI leaders, along with seasoned industry experts who have deep expertise in building, scaling, and optimizing enterprise workflows worldwide. Medeon's end-to-end ServiceNow offerings and solutions are AI-native, outcome-oriented, and geared toward achieving tangible business results for enterprises. These include strategic consulting, product implementations, change management, managed services, and accelerator solutions — all designed to help clients simplify operations, achieve faster time-to-value, and stabilize underperforming environments. Medeon ensures measurable ROI at every stage of the AI transformation journey, driving tangible and sustained business outcomes. Rohit Gandhi, Group CEO, Apar Technologies Group, said:"This strategic investment reflects our commitment to expanding Apar's digital transformation portfolio and delivering greater value to our global clients. With Medeon's strong ServiceNow expertise complementing Apar's scale and reach, we are strengthening our ability to support enterprises in their transformation journeys." Sai Sudhakar, Co-Founder & CEO, Apar Technologies, added:"By combining Apar's global presence and delivery capabilities with Medeon's solid expertise in ServiceNow, we are uniquely positioned to provide end-to-end workflow transformation solutions for our enterprise and Government customers. This partnership will enable us to help clients optimize operations, accelerate efficiencies and achieve measurable business outcomes." Avinash Vastrad, CEO, Medeon, said:"We are thrilled to join hands with Apar Technologies. This partnership allows us to extend the reach of our innovative ServiceNow solutions to new markets and industries while benefiting from Apar's global scale and client relationships. Together, we will help enterprises unlock measurable value from their ServiceNow investments and shape the future of intelligent, AI-driven workflows." With this investment, Apar Technologies and Medeon are set to deliver smarter workflows, accelerated efficiency, and impactful business transformation for organizations worldwide.
Expands Lender Relationships to Further Support Platform's Growth DUBLIN and STAMFORD, Conn. and NEW YORK, June 11, 2025 /PRNewswire/ -- Phoenix Aviation Capital ("Phoenix" or "the Company"), a full-service aircraft lessor managed by AIP Capital ("AIP") and a portfolio company of funds advised or controlled by affiliates of BC Partners Advisors L.P. announced the closing of a $300 million senior secured credit facility ("the facility"). Royal Bank of Canada ("RBC") acted as Structured Agent. RBC, Citibank and Morgan Stanley acted as Joint Lead Arrangers. The facility will be used to refinance seven assets currently owned by Phoenix and provide future funding for new asset acquisitions. "This facility represents another key milestone in Phoenix's expansion of its lender group and availability of debt capital," said Jared Ailstock, Managing Partner at AIP. "We are grateful for the support from the bank group as we continue to execute on Phoenix's growth strategy." "Closing this facility through a combination of new lenders and existing banks demonstrates the support Phoenix and AIP have in the aviation bank market," said Patrick Schafer, Managing Director at BC Partners and board member of Phoenix. "The facility will provide Phoenix with additional capacity and flexibility to support the Company's airline customers." Vedder Price served as transaction counsel and PwC acted as tax advisor to Phoenix and AIP. McCann Fitzgerald also acted in capacity as Irish counsel to Phoenix and AIP. Clifford Chance served as transaction counsel to the lenders. About AIP Capital AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $4 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of more than 30 experienced professionals across AIP's offices in Stamford, New York City, Dublin, and Singapore. For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com. About BC Partners & BC Partners Credit BC Partners is a leading international investment firm in private equity, private debt, and real estate strategies. BC Partners Credit was launched in February 2017, with a focus on identifying attractive credit opportunities in any market environment, often in complex market segments. The platform leverages the broader firm's deep industry and operating resources to provide flexible financing solutions to middle-market companies across Business Services, Industrials, Healthcare and other select sectors. For further information, visit www.bcpartners.com/credit-strategy. Media Contacts AIP CapitalGeoffrey Bayersinvestor.relations@aipcapital.com BC PartnersLuke CharalambousLuke.Charalambous@BCPartners.com+44 7775 180 721
A12 藝術空間
Financing agreements
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
